Pharmacologic Stress Agents for Cardiac Imaging

被引：1
作者：
Reyes E. [1 ,2 ]
Anagnostopoulos C. [3 ]
机构：
[1] National Heart and Lung Institute, Imperial College London, London
[2] Nuclear Medicine Department, Royal Brompton Hospital, London
[3] Centre for Clinical Research, Biomedical Research Foundation, Academy of Athens, 4 Soranou Ephessiou Street
来源：
Current Cardiovascular Imaging Reports | 2013年 / 6卷 / 4期
关键词：
Cardiac imaging; Coronary artery disease; Pharmacological stress;
D O I：
10.1007/s12410-013-9212-6
中图分类号：
学科分类号：
摘要：
Non-invasive cardiac imaging plays a major role in modern Cardiology and is becoming an essential step in the assessment of patients with known or suspected coronary artery disease. In this setting, cardiac imaging is combined with stress to assess the functional significance of coronary stenosis. Dynamic exercise is the most physiological form of stress and hence it is regarded as the stress modality of choice. When exercise is not possible, pharmacological stress can be used as an effective and safe alternative. We here describe the mechanism of action, protocols, indications and contraindications as well as the diagnostic performance and safety profile of all pharmacological agents currently available for stress imaging with an emphasis on the newly developed A2A adenosine receptor agonist, regadenoson. © 2013 Springer Science+Business Media New York.
引用
收藏
页码：369 / 378
页数：9
相关论文
共 64 条
  • [1] Gould, K.L., Lipscomb, K., Effects of coronary stenoses on coronary flow reserve and resistance (1974) Am J Cardiol, 34, pp. 48-55
  • [2] Gibbons, R.J., Balady, G.J., Bricker, J.T., ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines) (2002) Circulation, 106 (14), pp. 1883-1892
  • [3] Picano, E., Dipyridamole-echocardiography test: historical background and physiologic basis (1989) Eur Heart J, 10, pp. 365-376
  • [4] Reyes, E., Stirrup, J., Roughton, M., D'Souza, S., Underwood, S.R., Anagnostopoulos, C., Attenuation of adenosine-induced myocardial perfusion heterogeneity by atenolol and other cardioselective beta-adrenoceptor blockers: a crossover myocardial perfusion imaging study (2010) J Nucl Med, 51 (7), pp. 1036-1043
  • [5] Taillefer, R., Ahlberg, A.W., Masood, Y., Acute beta-blockade reduces the extent and severity of myocardial perfusion defects with dipyridamole Tc-99m sestamibi SPECT imaging (2003) J Am Coll Cardiol, 42 (8), pp. 1475-1483
  • [6] Sharir, T., Rabinowitz, B., Livschitz, S., Underestimation of extent and severity of coronary artery disease by dipyridamole stress thallium-201 single-photon emission computed tomographic myocardial perfusion imaging in patients taking antianginal drugs (1998) J Am Coll Cardiol, 31 (7), pp. 1540-1546
  • [7] Anagnostopoulos, C., Harbinson, M., Kelion, A., Procedure guidelines for radionuclide myocardial perfusion imaging (2004) Heart, 90 (SUPPL. 1), pp. i1-10
  • [8] Henzlova, M., Cerqueira, M.D., Hansen, C., Taileffer, R., Siu-Sun, Y., ASNC Imaging Guidelines for Nuclear Cardiology Procedures: Stress protocols and tracers American Society of Nuclear Cardiology (ASNC) 2009, , http://www.asnc.org/section_73.cfm.01/02/2010
  • [9] Fredholm, B.B., IJzerman, A.P., Jacobson, K.A., Klotz, K.N., Linden, J., International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors (2001) Pharmacol Rev, 53 (4), pp. 527-552
  • [10] Mubagwa, K., Flameng, W., Adenosine, adenosine receptors and myocardial protection: an updated overview (2001) Cardiovasc Res, 52 (1), pp. 25-39
1234567